专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5914242A Method for diminishing myocardial infarction using protein phosphatase inhibitors 失效
标题翻译：使用蛋白磷酸酶抑制剂减少心肌梗死的方法
公开(公告)号：US5914242A
公开(公告)日：1999-06-22
申请号：US941964
申请日：1997-10-01
申请人： Richard Eric Honkanen , James M. Downey
发明人： Richard Eric Honkanen , James M. Downey
IPC分类号： A61K31/665 , A61K38/00 , C12Q1/42 , C12Q1/00 , G01N33/53
CPC分类号： A61K31/665 , A61K38/005 , C12Q1/42
摘要： Fostriecin and a compounds structurally related to fostriecin diminish myocardial infarction and delay the onset of cell injury in an ischemic heart. There is a strong correlation between myocardial protection and the inhibition of certain serine/threonine protein phosphatases. The present invention is drawn to a method for administering fostriecin as a pharmacological compound to reduce the size of a myocardial infarction. Further, administration of fostriecin is useful also as an adjunct therapy to treatment with thrombolytic agents or angioplasty to limit the size of infarction. The most advantageous feature of the method of the present invention is that administration of fostriecin diminishes infarct volume and cell injury even when added after ischemia conditions occurred. In addition to the use of the method of the present invention for limiting damage due to myocardial infarction, the method of the present invention can be employed to delay damage associated with tissue storage for organ transplantation.
摘要翻译：福斯特因及其与fostriecin结构相关的化合物减少心肌梗塞并延缓缺血性心脏细胞损伤的发生。心肌保护与某些丝氨酸/苏氨酸蛋白磷酸酶的抑制有很强的相关性。本发明涉及一种施用作为药理化合物的骨菌素以减少心肌梗塞的大小的方法。此外，对于治疗血栓溶解剂或血管成形术来限制梗塞的大小，福斯特林的给药也可用作辅助治疗。本发明方法的最有利特征在于，即使在局部缺血病症发生后加入，三聚氰胺的施用也会降低梗死体积和细胞损伤。除了使用本发明的方法以限制由于心肌梗塞引起的损伤之外，本发明的方法可用于延迟与用于器官移植的组织储存有关的损伤。

IPRDB

热门服务

关于我们

友情链接

联系方式